Clinical pharmacology of rapacuronium bromide, a new short-acting neuromuscular blocking agent.
Rapacuronium is a new steroidal, nondepolarizing, neuromuscular blocking agent. It appears to be the least potent of all available nondepolarizing muscle relaxants. Its onset of action resembles that of succinylcholine, and its recovery times are shorter than those of other nondepolarizing agents. The clinical duration of rapacuronium can be shortened significantly with early (2 min) administration of neostigmine, which may be beneficial in patients with difficult airway or failed intubation. Rapacuronium appears to be free of significant cardiovascular complications.
Larijani
G E
GE
Department of Anesthesiology, University of Medicine and Dentistry of New Jersey, Cooper Hospital, Camden 08103, USA.
Zafeiridis
A
A
Goldberg
M E
ME
D000328:Adult; D002319:Cardiovascular System / Q000187:drug effects*; D002986:Clinical Trials as Topic; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D003473:Neuromuscular Nondepolarizing Agents / Q000009:adverse effects* / Q000494:pharmacology*; D013997:Time Factors; D014673:Vecuronium Bromide / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000494:pharmacology
D003473:Neuromuscular Nondepolarizing Agents; D014673:Vecuronium Bromide; C082938:rapacuronium